Nanyang Biologics

Name

Nanyang Biologics

Legal name

NYB Group

Website

https://nanyangbiologics.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

AI-Driven Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF)

Keywords

• AI drug discovery
• Natural compound screening
• Bioactivity prediction
• Therapeutic development
• Nutraceutical products

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

1. AI Discovery Platform Services: Providing AI-powered compound screening and bioactivity prediction services to pharmaceutical, biotech, and nutraceutical companies on a contract/research services basis.
2. Therapeutic Drug Development: Advancing compounds from discovery through preclinical development toward clinical candidates, targeting oncology, metabolic health, and healthy aging indications.
3. Nutraceutical Product Development: Science-validated wellness products developed from natural compounds, with identified dosages for real-world efficacy in mental health, solid tumors, and metabolic disease applications.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Nanyang Biologics operates an AI-first drug discovery and nutraceuticals platform built on one of the world's largest natural compound libraries (over 1.5 million compounds) combined with proprietary graph neural network and molecular modelling capabilities for bioactivity prediction. The company delivers three integrated product lines: AI-First Discovery Platform services for compound screening, a Therapeutics pipeline advancing candidates such as NB-A002 for DDR/HRD cancers toward preclinical development, and Nutraceutical products translating science-validated dosages into proactive wellness offerings.

Product overview

Nanyang Biologics (NYB Group) operates an integrated AI-first drug discovery and nutraceuticals platform organized around three pillars: an AI-First Discovery Platform (comprising a Natural Compound Library of 1.5M+ compounds and proprietary Bioactivity Prediction Models using Graph Neural Networks), a Therapeutics pipeline (advancing candidates like NB-A002 for DDR/HRD cancers, plus programs in oncology, healthy aging, and metabolic health), and a Nutraceuticals line (science-backed wellness products targeting mental health, solid tumors, and metabolic disease). The company also has a spinoff entity, NYB.AI, focused on AI drug discovery and featured at NVIDIA GTC Taiwan 2026. The platform's core differentiator is a 40% hit rate for AI-prioritized candidates and 27.03% greater bioactivity prediction accuracy versus leading industry models.

Differentiator

Problem solved

Functional benefit

Brands

• NYB.AI: AI drug discovery spinoff of NYB Group, featured at NVIDIA GTC Taiwan 2026 in Jensen Huang's keynote.

Products and services

• AI-First Discovery Platform

Quantifiable outcome

• 27.03% greater accuracy in bioactivity prediction vs leading industry models
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and supporting.

• NVIDIAcoreTechnology or Integration · 16 March 2026NYB.AI, the AI drug discovery spinoff of NYB Group, was featured in Jensen Huang's keynote at NVIDIA GTC Taiwan 2026, recognized among world's leading AI innovators from NVIDIA Inception's ecosystem of 25,000+ startups. NYB exhibited at NVIDIA GTC 2026 and reflects on participation in GTC 2026 for scientific exchange and cross-sector dialogue.
• Hewlett Packard EnterprisesupportingTechnology or IntegrationFeatured as a supporter on NYB Group's website, indicating infrastructure/technology support partnership for the company's AI drug discovery operations.
• EquinixsupportingTechnology or IntegrationFeatured as a supporter on NYB Group's website, indicating data center/infrastructure support for the company's computational needs.
• Strategic Tech AlliancescoreTechnology or IntegrationNYB Group maintains a category of strategic technology alliance partners, though specific named companies are not listed on the homepage. These alliances support the AI-first discovery platform capabilities.
• Research & Academic PartnerscoreStrategic or Co-development PartnerNYB Group maintains partnerships with research institutions and academic organizations for drug discovery research and development collaboration.
• Discovery & Industry PartnerscoreStrategic or Co-development PartnerIndustry partners collaborating on AI-driven drug discovery projects, though specific company names are not detailed on the homepage.
• AcceleratorssupportingStrategic or Co-development PartnerNYB Group is associated with accelerator programs supporting startup development and growth within the biotech ecosystem.
• Commercial & Distribution PartnerssupportingChannel Partner/ Reseller/ DistributorPartners supporting commercialization and distribution of nutraceutical products and services, though specific partner names are not listed.

Scale indicators7 records

Recent moves7 records

Expansion highlights3 records

Direct peers

• Insilico Medicine: AI-driven drug discovery company combining generative chemistry, deep learning, and biology to identify novel therapeutics. Most directly comparable to NYB on AI-first discovery, natural product/molecular datasets, and a therapeutics pipeline that progressed to clinical stage.
• Recursion Pharmaceuticals: Publicly listed AI drug discovery company using high-throughput biology data and machine learning to identify novel therapeutic targets. Directly comparable to NYB on combining proprietary datasets with ML models for drug discovery, at a more mature and capitalized stage.
• Exscientia: Pioneer in AI-driven small molecule drug design, combining automated design platforms with pharma partnerships and an internal pipeline. Comparable to NYB on AI-first discovery services with pharma clients and on advancing AI-discovered candidates into development.
• Atomwise: AI drug discovery company using graph neural networks and structural-based drug design to predict binding and bioactivity of small molecules. Closely matched to NYB on the GNN/structure-based prediction approach and a services-led model partnering with pharma.
• XtalPi: Asia-based AI and quantum-physics-driven drug discovery company offering platform services and an internal pipeline. Comparable to NYB on the AI-first, Asia-based positioning, with deeper capital base and broader pharma partnerships.
• BenevolentAI: AI drug discovery company using knowledge graphs and ML to identify novel drug targets and molecules. Comparable to NYB on AI-first discovery, target identification, and partnerships with large pharma for clinical translation.

Broad incumbents

• Schrödinger, Inc. Publicly listed computational chemistry and biology software and drug discovery company. Comparable to NYB on AI/molecular modeling-driven compound evaluation, but operates as a broader platform serving pharma with both software licensing and proprietary programs.
• Isomorphic Labs: Alphabet-backed AI drug discovery company building computational models for biology. Comparable to NYB on AI-first, deep-learning-driven small molecule and biologics design, but with materially deeper resources and a focus on platform-level pharma partnerships.

Emerging players

• Bota Bio: Singapore-based synthetic biology and AI-guided bioengineering company. Comparable to NYB on geography (Singapore HQ), natural-product/biologics focus, and AI-driven bio-R&D, although focused on industrial/synthetic biology applications rather than therapeutics.

Regional players

• A*STAR Genome Institute of Singapore: Singapore-based public research institute conducting biologics, genomics, and bio-IT research. Comparable to NYB on Singapore biotech ecosystem footprint and on combining biological data with computational methods, though not a commercial discovery platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/nanyang-biologics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nanyang Biologics